USPTO Patent Application: Recombinant Human Type III Collagen for Angiogenesis

ChangeBridge: Patent Apps - Peptides (C07K)

Published March 26th, 2026

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260083883A1) detailing recombinant human type III collagen designed to promote angiogenesis. The application describes modifications to natural type III collagen to enhance its angiogenic function and adhesion properties, potentially increasing the angiogenesis rate by over 37%.

View original document View source feed page

What changed

This document is a USPTO patent application (US20260083883A1) for a modified recombinant human type III collagen intended to promote angiogenesis. The innovation involves replacing specific amino acid sites in natural type III collagen with sequences from type I collagen to enhance integrin binding and adhesion, thereby improving the promotion of angiogenesis by more than 37%. The application also covers methods for preparing and applying this modified collagen.

As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it signals potential future developments in therapeutic areas related to wound healing, tissue regeneration, and cardiovascular treatments. Companies operating in the biotechnology and pharmaceutical sectors, particularly those involved in regenerative medicine or biomaterials, should be aware of this patent filing as it may impact future research, development, and intellectual property landscapes.

Source document (simplified)

← USPTO Patent Applications

RECOMBINANT HUMAN TYPE III COLLAGEN FOR PROMOTING ANGIOGENESIS, AND PREPARATION METHOD AND APPLICATION METHOD THEREOF

Application US20260083883A1 Kind: A1 Mar 26, 2026

Inventors

Weina Li, Yaqian Zhang, Daidi Fan, Xinyue Deng, Yanting Yuan, Qiyi Jiang, Ziyang Niu, Jingwen Zhai, Linmiao Song, Min Yang, Zhe Wan, Xinzheng Fu, Tingyuan Xiao

Abstract

Recombinant human type III collagen for promoting angiogenesis, and a preparation method and an application method thereof are provided, which relate to the field of genetic engineering technologies. The amino acid of the recombinant human type III collagen is as shown in SEQ ID NO: 1. The method replaces nine different sites of a full-length natural type III collagen with a GFOGER sequence from type I collagen specifically binding to integrin sites, thereby enhancing promote angiogenic function without changing a total length of natural full-length amino acids. Meanwhile, the method replaces four natural integrin sites with lower adhesion rates, thus the recombinant type III collagen have higher adhesion, to further promote angiogenesis. Through this modification method, the angiogenesis rate will be increased by more than 37%, and the molecular weight of protein translated by the recombinant human type III collagen is moderate, making it easy to prepare.